Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for DaVita Inc. (DVA : NYSE)

• Company Description    DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services. Number of Employees: 78,000

• Price / Volume Information    Yesterday's Closing Price: $151.85 Daily Weekly Monthly 20 Day Moving Average: 624,713 shares Shares Outstanding: 66.80 (millions) Market Capitalization: $10,143.58 (millions) Beta: 0.92 52 Week High: $159.42 52 Week Low: $101.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.67% -12.60% 12 Week 38.88% 34.50% Year To Date 33.66% 27.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2000 16TH STREET - DENVER,CO 80202 USA ph: 720-631-2100 fax: 302-636-5454 ir@davita.com http://www.davita.com

• General Corporate Information    Officers Javier J. Rodriguez - Chief Executive Officer and Director Joel Ackerman - Chief Financial Officer and Treasurer Christopher M. Berry - Chief Accounting Officer Pamela M. Arway - Director Barbara J. Desoer - Director Peer Information DaVita Inc. (CMTI) DaVita Inc. (CMWLQ) DaVita Inc. (AHG.) DaVita Inc. (ROIX) DaVita Inc. (M.DCE) DaVita Inc. (DHSM) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-OUTP/HM CRE Sector: Medical CUSIP: 23918K108 SIC: 8090 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/05/26 Share - Related Items Shares Outstanding: 66.80 Most Recent Split Date: 9.00 (2.00:1) Beta: 0.92 Market Capitalization: $10,143.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $3.80 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $14.16 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 20.25% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/05/26

• Fundamental Ratios P/E Current FY Estimate: 10.73 Trailing 12 Months: 13.98 PEG Ratio: 0.53 Price Ratios Price/Book: - Price/Cash Flow: 6.99 Price / Sales: 0.74 EPS Growth vs. Year Ago Period: 51.79% vs. Previous Quarter: 35.46% Sales Growth vs. Year Ago Period: 9.87% vs. Previous Quarter: 5.83% ROE 03/31/26 - - 12/31/25 - -413.18 09/30/25 - -13,370.89 ROA 03/31/26 - - 12/31/25 - 4.70 09/30/25 - 4.41 Current Ratio 03/31/26 - - 12/31/25 - 1.29 09/30/25 - 1.36 Quick Ratio 03/31/26 - - 12/31/25 - 1.24 09/30/25 - 1.32 Operating Margin 03/31/26 - - 12/31/25 - 6.00 09/30/25 - 5.74 Net Margin 03/31/26 - - 12/31/25 - 5.47 09/30/25 - 5.80 Pre-Tax Margin 03/31/26 - - 12/31/25 - 9.87 09/30/25 - 10.35 Book Value 03/31/26 - - 12/31/25 - -5.29 09/30/25 - -4.31 Inventory Turnover 03/31/26 - - 12/31/25 - 61.98 09/30/25 - 63.52 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©